Gaál et al. evaluated the effect of systemic alphacalcidol on several immunologic aspects in subjects with psoriasis and revealed that this intervention resulted in a statistically significant decrease in CD3+/CD69+ PBMCs, together with a continuous decrease in symptoms of the disease [27]. The gene discussed is CD69; the disease is psoriasis.